Repros terapéutica stock
THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) ("Repros" or the "Company") today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the Repros Therapeutics, Inc. RPRX Stock Message Board: Do you know the blog site name? Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United RPRX stock rating and analysis - Repros Therapeutics : a summary of key financial strength and profitability metrics. KPTI (Karyopharm Therapeutics, Inc.) vs. RPRX (Repros Therapeutics Inc.) stock comparison side-by-side research /w SpeculatingStocks FREE tool. If you acquired common stock in Repros Therapeutics, Inc. between January 1, 2009 and July 31, 2009 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.
(OPENPRESS) August 19, 2009 -- Repros Therapeutics, Inc. faces a securities class action lawsuit over alleged violations of Federal Securities Laws on behalf of purchasers of the common stock of Repros Therapeutics, Inc. (NASDAQ: RPRX) common stock from July 1, 2009 through August 3, 2009.
Repros Therapeutics Inc(RPRX) either stopped trading, was acquired or changed ticker symbols. You can still view historical stock and dividend information for Repros Therapeutics Inc by scrolling below. / Barchart Opinions show traders what a variety of popular trading systems are suggesting in terms of going long or short the market. The Opinions takes up to 5 years' worth of historical data and runs these prices through thirteen different technical indicators. Repros Therapeutics Inc., a development stage biopharmaceutical company, focused on the development of new drugs to treat hormonal and reproductive system disorders. It is developing Androxal, an oral therapy that normalizes testicular function for the treatment of low testosterone due to secondary hypogonadism. Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates on Behalf of Shareholders Robbins LLP are investigating potential violations of federal securities laws on behalf of investors of Repros Therapeutics, Inc. (NASDAQ: RPRX). Repros Therapeutics is a development stage biopharmaceutical company, engaged in the development of new drugs to treat hormonal and reproductive system View detailed financial information, real-time news, videos, quotes and analysis on Repros Therapeutics Inc. (NASDAQ:RPRX). Explore commentary on Repros Therapeutics Inc. and hear what the experts Repros' stock was down nearly 65 percent year-to-date, having fallen from about $1.37 per share at the beginning of the year to close at 47 cents Dec. 11, according to Yahoo Finance. Repros assumes no obligation and does not intend to update these forward-looking statements, except as expressly required by law. Notice to Investors. The tender offer for the outstanding shares of common stock of Repros referred to in this press release has not yet commenced.
Repros Therapeutics (RPRX) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.
Learn how to trade big board and penny stocks by learning to read stock charts and identify technical patterns through technical analysis. Follow along and learn as I perform a quick stock chart technical analysis review on the Repros Therapeutics, Inc (RPRX) chart. Repros Therapeutics Inc (NASDAQ:RPRX) Repros Therapeutics Inc (NASDAQ:RPRX) has entered into an underwriting agreement that will see the company sell a total of 2,744,125 shares of the Company's common stock in a public offering. The agreement will also involve issuing pre-funded Series C warrants to buy 2,245,875 shares of Common Stock that will be offered in lieu of Common Stock to those THE WOODLANDS, Texas, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) ("Repros" or the "Company") today announced that it has entered into a definitive agreement NEW YORK -- Repros Therapeutics stock is falling 26.09% to $1.77 on heavy volume trading on Tuesday, after the FDA expressed concerns about the company's reproductive drug.The FDA recommended that Repros Therapeutics Inc. (NASDAQ: RPRX) closed at per share at the end of the most recent trading day (a % change compared to the prior day closing price) with a volume of 0.0000 shares and market capitalization of 26.51M.Is a component of indexes and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people.
The requested symbol was not found in our database. Try searching for some other symbol on Yahoo Finance
Repros Therapeutics Inc., a development stage biopharmaceutical company, focused on the development of new drugs to treat hormonal and reproductive system disorders. It is developing Androxal, an oral therapy that normalizes testicular function for the treatment of low testosterone due to secondary hypogonadism. Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates on Behalf of Shareholders Robbins LLP are investigating potential violations of federal securities laws on behalf of investors of Repros Therapeutics, Inc. (NASDAQ: RPRX). Repros Therapeutics is a development stage biopharmaceutical company, engaged in the development of new drugs to treat hormonal and reproductive system View detailed financial information, real-time news, videos, quotes and analysis on Repros Therapeutics Inc. (NASDAQ:RPRX). Explore commentary on Repros Therapeutics Inc. and hear what the experts Repros' stock was down nearly 65 percent year-to-date, having fallen from about $1.37 per share at the beginning of the year to close at 47 cents Dec. 11, according to Yahoo Finance.
Copies or reproductions of other publications will be allowed only with Financial relationships (such as employment, consultancies, stock owner- ship, honoraria de pacientes em uso de terapia anticoagulante por causa da prevalência de
As of December 31, 2016 we had 25,826,252 shares of common stock outstanding. About Repros Therapeutics Inc. ® Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. Repros Therapeutics Inc (NASDAQ: RPRX) Repros Therapeutics is having an incredible day in the market today, following up on gains we saw from the stock yesterday. The increases in value are happeni…
THE WOODLANDS, Texas, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (NASDAQ:RPRX) ("Repros" or the "Company") today announced that following an Oral Explanation, it has Repros Therapeutics Inc. (NASDAQ: a subsidiary of Allergan will commence a cash tender offer to purchase all of the outstanding shares of Repros common stock for $0.67 per share. The closing Repros Therapeutics (RPRX) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. Full Profile of RPRX (Repros Therapeutics Inc.) : Nasdaq Market Cap: 26.24M | Industry: Health Care/Life Sciences Repros Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of new drugs to treat hormonal and reproductive systems disorders. Its products include Enclophene and Proellex. Allergan is buying The Woodlands-based Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018. Repros is a development-stage biopharma company. Its focus is on oral small molecule drugs for male and female reproductive health. Date: Open: High: Low: Close: Volume: Chg % Chg: Adj. Close: Trade Val # Trades: Could not find information for the time period selected. Please ensure you have entered the date information in the correct format.